FINWIRES · TerminalLIVE
FINWIRES

Research Alert: Ccep Meets Q1 Estimates On Calendar Boost; Underlying Demand Growth Modest

By

-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

CCEP reported Q1 2026 revenue of EUR5.00B, in line with consensus of EUR4.99B. FXN revenue growth of 9.4% was led by strong reported volume growth of 8.5%, though comparable volume growth of 1.6% after adjusting for six additional consumption days provides a more accurate demand picture. Revenue per unit case growth was moderate at 0.8%, with Europe posting 1.3% expansion while APS declined 0.3% due to the Suntory alcohol exit impact. The energy category delivered exceptional 21.3% volume growth from Monster brand distribution gains. However, we do not expect sustainable outperformance given potential consumer choice overload from excessive innovation. Management reaffirmed 2026 targets of 3-4% FXN revenue growth and ~7% comparable operating profit growth, which compare well with consensus estimates. However, we maintain a grounded view given the challenging consumer environment with an ongoing focus on value and affordability, which limits price growth potential and necessitates sustained promotions.

Related Articles

Asia

ICBC Sells 50 Billion Yuan Bonds

Industrial and Commercial Bank of China (HKG:1398, SHA:601398) or ICBC completed the issue of 50 billion yuan of four-year bonds carrying an interest rate of 1.79%, according to a Wednesday Hong Kong bourse filing.The lender has a conditional redemption right at the end of the third year.The firm intends to use proceeds to improve its total loss-absorbing capacity.

$HKG:1398$SHA:601398
Asia

DFZQ's Profit Climbs 11% in Q1

Orient Securities (HKG:3958) or DFZQ recorded an 11% rise in attributable profit in the first quarter of 2026 to 1.59 billion yuan from 1.44 billion yuan after adjustment a year prior, according to a Wednesday Hong Kong bourse filing.The securities company's basic EPS rose to 0.19 yuan from 0.16 yuan in the corresponding period of the previous fiscal year.Operating income jumped 5.3% to 4.09 billion yuan from 3.88 billion yuan in the year-ago period.

$HKG:3958
Research

Research Alert: Ionis Reports Strong Q1 Led By Commercial Momentum; Raises Guidance

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Ionis delivered robust Q1 2026 results with total revenue surging to $246M (+87% Y/Y), fueled by strong commercial execution and approximately $95M in R&D milestone payments. Product sales reached $43M compared to just $6M in the prior year period, with TRYNGOLZA generating $27M (+350% Y/Y) and DAWNZERA contributing $16M (+125% sequential growth). The accelerating momentum across its independent launch portfolio demonstrates strong commercial execution, in our view. Management raised 2026 revenue guidance substantially to $875M-$900M (from $800M-$825M) and improved operating loss guidance to $425M-$475M (from $500M-$550M). The company also increased olezarsen peak sales guidance to over $3B from over $2B, reflecting growing confidence in the severe hypertriglyceridemia market opportunity. With multiple regulatory catalysts ahead, including potential approvals for olezarsen and zilganersen, we believe Ionis appears well-positioned for continued growth.

$IONS